PTN Palatin Technologies Inc.

FDA Catalyst Company
0.4
+0.01  (+3%)
Previous Close 0.39
Open 0.4
52 Week Low 0.315
52 Week High 0.96
Market Cap $92,678,109
Shares 231,695,273
Float 227,457,876
Enterprise Value $39,780,124
Volume 577,214
Av. Daily Volume 921,761
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
HC Wainwright & Co. Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 11/24/2021

Latest News

    • Patient Enrollment on Track in Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease with Topline Results Currently Expected Second Half Calendar 2022
    • Vyleesi® - Gross product sales increased 67%, net product revenue increased 200% and prescriptions dispensed increased 20%, over the prior quarter
    • Closed on a $15 Million Private Placement of Convertible Redeemable Preferred Stock
    • Phase 2 Clinical Study of PL8177 in Patients with Ulcerative Colitis Expected to Start Next Month with Topline Results Currently Expected First Quarter Calendar 2023
    • Teleconference and Webcast to be held on May 17, 2022 at 11:00 AM EDT

    CRANBURY, N.J., May 17, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN), a biopharmaceutical company developing first-in-class…

    View Full Article
  1. CRANBURY, N.J., May 12, 2022 /PRNewswire/ -- Palatin Technologies, Inc. ("Palatin" or the "Company") (NYSE:PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced  that it has entered into a securities purchase agreement with institutional investors pursuant to which Palatin will issue and sell 8,100,000 shares of its Series B convertible redeemable preferred stock and 900,000 shares of its Series C convertible redeemable preferred stock to such investors. Each share of Series B and Series C preferred stock has a purchase price of $1.67. Each share of Series B and Series C preferred stock is convertible into shares of Palatin's…

    View Full Article
  2. Presentation to review the role of melanocortins in the treatment of ocular disease and Phase 2 study results with Palatin's compound PL9643 for Dry Eye Disease

    PL9643 Dry Eye Disease Phase 3 study ongoing - data expected 4Q 2022

    CRANBURY, N.J., April 21, 2022 /PRNewswire/ -- Palatin Technologies, Inc. ("Palatin") (NYSE:PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced that Carl Spana, Ph.D., President and CEO of Palatin, will deliver a presentation today at the [email protected] 2022 Conference in Washington D.C. 

    View Full Article
View All Palatin Technologies Inc. News